 Nancy Reau
Concepts (219)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hepatitis C, Chronic | 27 | 2021 | 82 | 9.510 |
Why?
| | Antiviral Agents | 30 | 2021 | 138 | 9.160 |
Why?
| | Hepatitis C | 17 | 2021 | 65 | 6.450 |
Why?
| | Hepacivirus | 19 | 2021 | 71 | 4.200 |
Why?
| | Liver Diseases | 9 | 2021 | 39 | 3.530 |
Why?
| | Liver Transplantation | 7 | 2021 | 107 | 2.950 |
Why?
| | Ribavirin | 9 | 2016 | 32 | 2.120 |
Why?
| | Pregnancy Complications | 5 | 2019 | 56 | 2.020 |
Why?
| | Liver Cirrhosis | 10 | 2019 | 61 | 1.740 |
Why?
| | Sulfonamides | 7 | 2020 | 63 | 1.560 |
Why?
| | Hepatitis B | 5 | 2019 | 20 | 1.540 |
Why?
| | Pregnancy Complications, Infectious | 2 | 2019 | 34 | 1.500 |
Why?
| | Polyethylene Glycols | 5 | 2012 | 55 | 1.480 |
Why?
| | Interferon-alpha | 5 | 2012 | 82 | 1.480 |
Why?
| | Humans | 53 | 2021 | 29841 | 1.200 |
Why?
| | Pregnancy | 8 | 2021 | 443 | 1.190 |
Why?
| | Carbamates | 8 | 2020 | 9 | 1.190 |
Why?
| | Drug Therapy, Combination | 13 | 2021 | 264 | 1.120 |
Why?
| | Quinoxalines | 4 | 2020 | 10 | 1.110 |
Why?
| | Infectious Disease Transmission, Vertical | 2 | 2019 | 19 | 1.040 |
Why?
| | Gastroenterology | 3 | 2017 | 16 | 1.010 |
Why?
| | Living Donors | 1 | 2021 | 16 | 0.960 |
Why?
| | United States | 15 | 2021 | 2402 | 0.900 |
Why?
| | Thrombocytopenia | 1 | 2020 | 31 | 0.900 |
Why?
| | Treatment Outcome | 19 | 2021 | 3788 | 0.890 |
Why?
| | Postoperative Hemorrhage | 1 | 2020 | 30 | 0.880 |
Why?
| | Benzimidazoles | 3 | 2019 | 12 | 0.880 |
Why?
| | Elective Surgical Procedures | 1 | 2020 | 53 | 0.880 |
Why?
| | Kidney Transplantation | 2 | 2018 | 143 | 0.840 |
Why?
| | Hypertension, Pregnancy-Induced | 1 | 2019 | 1 | 0.830 |
Why?
| | Genotype | 10 | 2017 | 435 | 0.830 |
Why?
| | Female | 30 | 2021 | 17657 | 0.790 |
Why?
| | Viral Load | 5 | 2016 | 208 | 0.780 |
Why?
| | Algorithms | 2 | 2020 | 414 | 0.760 |
Why?
| | Fear | 1 | 2018 | 49 | 0.760 |
Why?
| | Cholestasis, Intrahepatic | 3 | 2019 | 6 | 0.760 |
Why?
| | Drugs, Generic | 1 | 2016 | 4 | 0.690 |
Why?
| | HIV Infections | 3 | 2019 | 902 | 0.680 |
Why?
| | Antacids | 1 | 2016 | 1 | 0.680 |
Why?
| | Proton Pump Inhibitors | 1 | 2016 | 15 | 0.680 |
Why?
| | Pregnancy Complications, Neoplastic | 1 | 2016 | 4 | 0.670 |
Why?
| | Virology | 1 | 2015 | 16 | 0.650 |
Why?
| | Patient Readmission | 1 | 2016 | 111 | 0.600 |
Why?
| | Length of Stay | 2 | 2016 | 360 | 0.580 |
Why?
| | Coinfection | 3 | 2019 | 33 | 0.570 |
Why?
| | Preventive Health Services | 1 | 2013 | 15 | 0.550 |
Why?
| | Adult | 19 | 2021 | 9591 | 0.540 |
Why?
| | Advisory Committees | 1 | 2013 | 43 | 0.540 |
Why?
| | Health Policy | 1 | 2013 | 49 | 0.530 |
Why?
| | Middle Aged | 20 | 2020 | 11053 | 0.530 |
Why?
| | Heart Failure | 1 | 2016 | 222 | 0.510 |
Why?
| | Disease Management | 2 | 2016 | 149 | 0.490 |
Why?
| | Liver | 2 | 2018 | 213 | 0.480 |
Why?
| | Imidazoles | 4 | 2020 | 72 | 0.450 |
Why?
| | Macrocyclic Compounds | 4 | 2019 | 6 | 0.440 |
Why?
| | Pregnancy Outcome | 2 | 2021 | 20 | 0.440 |
Why?
| | Recombinant Proteins | 5 | 2012 | 306 | 0.440 |
Why?
| | Male | 22 | 2021 | 17153 | 0.430 |
Why?
| | Drug Resistance, Viral | 4 | 2017 | 43 | 0.430 |
Why?
| | Bile Ducts, Intrahepatic | 1 | 2008 | 7 | 0.380 |
Why?
| | Drug Administration Schedule | 3 | 2018 | 265 | 0.380 |
Why?
| | Aged | 14 | 2020 | 9833 | 0.380 |
Why?
| | Fatty Liver | 2 | 2019 | 40 | 0.360 |
Why?
| | Anemia | 1 | 2008 | 90 | 0.360 |
Why?
| | Retrospective Studies | 8 | 2020 | 3303 | 0.360 |
Why?
| | Cohort Studies | 6 | 2021 | 1911 | 0.360 |
Why?
| | Medication Adherence | 2 | 2019 | 87 | 0.350 |
Why?
| | Liver Neoplasms | 2 | 2019 | 124 | 0.340 |
Why?
| | Liver Function Tests | 2 | 2019 | 32 | 0.330 |
Why?
| | Benzofurans | 3 | 2020 | 6 | 0.320 |
Why?
| | Graft Rejection | 2 | 2018 | 85 | 0.310 |
Why?
| | Societies, Medical | 2 | 2017 | 202 | 0.300 |
Why?
| | Drug Interactions | 2 | 2015 | 71 | 0.290 |
Why?
| | Mass Screening | 3 | 2015 | 193 | 0.290 |
Why?
| | Cyclopropanes | 2 | 2020 | 8 | 0.280 |
Why?
| | Incidence | 2 | 2020 | 813 | 0.280 |
Why?
| | Prospective Studies | 4 | 2019 | 1809 | 0.280 |
Why?
| | Amides | 2 | 2020 | 23 | 0.270 |
Why?
| | Uracil | 3 | 2019 | 5 | 0.270 |
Why?
| | Young Adult | 7 | 2020 | 2198 | 0.270 |
Why?
| | Ritonavir | 3 | 2019 | 18 | 0.270 |
Why?
| | Risk Assessment | 3 | 2018 | 794 | 0.270 |
Why?
| | Prognosis | 3 | 2018 | 1025 | 0.260 |
Why?
| | Chronic Disease | 3 | 2020 | 530 | 0.250 |
Why?
| | Fertility | 1 | 2021 | 15 | 0.240 |
Why?
| | Graft Survival | 2 | 2019 | 111 | 0.240 |
Why?
| | Aged, 80 and over | 8 | 2020 | 5016 | 0.230 |
Why?
| | World Health Organization | 1 | 2020 | 20 | 0.230 |
Why?
| | Cost-Benefit Analysis | 3 | 2019 | 144 | 0.230 |
Why?
| | Tissue Donors | 1 | 2021 | 71 | 0.230 |
Why?
| | End Stage Liver Disease | 1 | 2020 | 17 | 0.230 |
Why?
| | Anilides | 2 | 2019 | 11 | 0.220 |
Why?
| | Hemorrhage | 1 | 2020 | 87 | 0.220 |
Why?
| | Recurrence | 2 | 2011 | 383 | 0.220 |
Why?
| | Consensus | 2 | 2021 | 90 | 0.210 |
Why?
| | Drug and Narcotic Control | 2 | 2016 | 8 | 0.210 |
Why?
| | Hyperemesis Gravidarum | 1 | 2019 | 1 | 0.210 |
Why?
| | Hepatitis, Autoimmune | 1 | 2019 | 8 | 0.210 |
Why?
| | Carcinoma, Hepatocellular | 1 | 2019 | 44 | 0.210 |
Why?
| | Forecasting | 1 | 2019 | 129 | 0.200 |
Why?
| | United States Food and Drug Administration | 2 | 2016 | 77 | 0.200 |
Why?
| | Biomedical Research | 1 | 2019 | 85 | 0.200 |
Why?
| | Transplant Recipients | 1 | 2018 | 18 | 0.200 |
Why?
| | Internationality | 1 | 2018 | 26 | 0.190 |
Why?
| | Logistic Models | 2 | 2010 | 478 | 0.190 |
Why?
| | RNA, Viral | 3 | 2018 | 169 | 0.190 |
Why?
| | Follow-Up Studies | 4 | 2015 | 2017 | 0.190 |
Why?
| | Practice Guidelines as Topic | 3 | 2021 | 382 | 0.190 |
Why?
| | Drug Substitution | 1 | 2017 | 3 | 0.180 |
Why?
| | Critical Pathways | 1 | 2017 | 23 | 0.180 |
Why?
| | Risk Factors | 3 | 2020 | 2549 | 0.180 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2018 | 524 | 0.180 |
Why?
| | Infant, Newborn | 1 | 2019 | 741 | 0.180 |
Why?
| | Counterfeit Drugs | 1 | 2016 | 2 | 0.170 |
Why?
| | Patient Participation | 1 | 2017 | 51 | 0.170 |
Why?
| | Commerce | 1 | 2016 | 11 | 0.170 |
Why?
| | Ascites | 1 | 2016 | 5 | 0.170 |
Why?
| | Canada | 1 | 2016 | 55 | 0.170 |
Why?
| | Fraud | 1 | 2016 | 10 | 0.170 |
Why?
| | Paracentesis | 1 | 2016 | 4 | 0.170 |
Why?
| | Quality Control | 1 | 2016 | 48 | 0.170 |
Why?
| | Safety | 1 | 2016 | 57 | 0.170 |
Why?
| | Interferons | 1 | 2016 | 17 | 0.170 |
Why?
| | Eclampsia | 1 | 2016 | 2 | 0.170 |
Why?
| | Psychometrics | 1 | 2018 | 284 | 0.170 |
Why?
| | HELLP Syndrome | 1 | 2016 | 2 | 0.170 |
Why?
| | Pre-Eclampsia | 1 | 2016 | 8 | 0.170 |
Why?
| | Drug Approval | 1 | 2016 | 33 | 0.170 |
Why?
| | Time Factors | 3 | 2016 | 1894 | 0.160 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2016 | 172 | 0.160 |
Why?
| | Benchmarking | 1 | 2015 | 28 | 0.160 |
Why?
| | Directive Counseling | 1 | 2015 | 15 | 0.160 |
Why?
| | Hospitalization | 2 | 2016 | 330 | 0.160 |
Why?
| | Diffusion of Innovation | 1 | 2015 | 42 | 0.160 |
Why?
| | Benzazepines | 1 | 2015 | 10 | 0.160 |
Why?
| | Isoquinolines | 1 | 2015 | 17 | 0.160 |
Why?
| | Deficiency Diseases | 1 | 2015 | 2 | 0.160 |
Why?
| | Adolescent | 3 | 2020 | 2591 | 0.160 |
Why?
| | Administration, Oral | 1 | 2015 | 164 | 0.160 |
Why?
| | Liver Failure | 1 | 2015 | 13 | 0.160 |
Why?
| | Zinc | 1 | 2015 | 39 | 0.150 |
Why?
| | Kidney Failure, Chronic | 1 | 2017 | 168 | 0.150 |
Why?
| | Treatment Failure | 2 | 2017 | 186 | 0.150 |
Why?
| | Severity of Illness Index | 1 | 2020 | 1220 | 0.150 |
Why?
| | Indoles | 1 | 2015 | 68 | 0.150 |
Why?
| | Comorbidity | 4 | 2018 | 555 | 0.150 |
Why?
| | Phenotype | 1 | 2015 | 360 | 0.150 |
Why?
| | Off-Label Use | 1 | 2014 | 6 | 0.150 |
Why?
| | Hospitalists | 1 | 2014 | 6 | 0.150 |
Why?
| | African Americans | 1 | 2021 | 739 | 0.140 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2016 | 357 | 0.140 |
Why?
| | Internship and Residency | 1 | 2016 | 182 | 0.140 |
Why?
| | Multivariate Analysis | 2 | 2015 | 390 | 0.140 |
Why?
| | Health Care Costs | 1 | 2014 | 79 | 0.140 |
Why?
| | Cooperative Behavior | 1 | 2014 | 88 | 0.140 |
Why?
| | Drug Eruptions | 1 | 2013 | 18 | 0.130 |
Why?
| | Hematologic Diseases | 1 | 2013 | 18 | 0.130 |
Why?
| | Viral Nonstructural Proteins | 3 | 2017 | 9 | 0.130 |
Why?
| | Gastrointestinal Diseases | 1 | 2013 | 43 | 0.130 |
Why?
| | Monitoring, Immunologic | 1 | 2012 | 2 | 0.130 |
Why?
| | Quality of Health Care | 1 | 2014 | 134 | 0.130 |
Why?
| | Drug Combinations | 3 | 2017 | 86 | 0.130 |
Why?
| | Immunosuppression | 1 | 2012 | 38 | 0.130 |
Why?
| | Predictive Value of Tests | 2 | 2017 | 617 | 0.120 |
Why?
| | Cost of Illness | 1 | 2011 | 61 | 0.120 |
Why?
| | Drug Carriers | 1 | 2010 | 9 | 0.120 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2012 | 219 | 0.110 |
Why?
| | Models, Statistical | 1 | 2011 | 140 | 0.110 |
Why?
| | Polymerase Chain Reaction | 1 | 2010 | 208 | 0.110 |
Why?
| | Odds Ratio | 1 | 2010 | 328 | 0.100 |
Why?
| | Prevalence | 1 | 2011 | 533 | 0.100 |
Why?
| | Sensitivity and Specificity | 1 | 2011 | 592 | 0.100 |
Why?
| | Fluorenes | 2 | 2019 | 3 | 0.100 |
Why?
| | Hemoglobins | 1 | 2008 | 76 | 0.090 |
Why?
| | Clinical Trials as Topic | 1 | 2009 | 382 | 0.090 |
Why?
| | Cross-Sectional Studies | 2 | 2021 | 915 | 0.080 |
Why?
| | Hospital Costs | 2 | 2016 | 74 | 0.070 |
Why?
| | Non-alcoholic Fatty Liver Disease | 1 | 2019 | 4 | 0.050 |
Why?
| | Quality-Adjusted Life Years | 1 | 2019 | 23 | 0.050 |
Why?
| | Waiting Lists | 1 | 2019 | 19 | 0.050 |
Why?
| | Tissue and Organ Procurement | 1 | 2019 | 36 | 0.050 |
Why?
| | Liver Diseases, Alcoholic | 1 | 2019 | 42 | 0.050 |
Why?
| | Insurance, Major Medical | 1 | 2018 | 1 | 0.050 |
Why?
| | International Normalized Ratio | 1 | 2018 | 32 | 0.050 |
Why?
| | Registries | 1 | 2019 | 195 | 0.050 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2017 | 40 | 0.050 |
Why?
| | Uridine Monophosphate | 1 | 2017 | 2 | 0.050 |
Why?
| | Genetic Variation | 1 | 2017 | 117 | 0.040 |
Why?
| | Decision Support Techniques | 1 | 2017 | 54 | 0.040 |
Why?
| | Delivery of Health Care, Integrated | 1 | 2017 | 30 | 0.040 |
Why?
| | Serine Proteases | 1 | 2016 | 7 | 0.040 |
Why?
| | Internal Medicine | 1 | 2016 | 30 | 0.040 |
Why?
| | Career Choice | 1 | 2016 | 32 | 0.040 |
Why?
| | Patient-Centered Care | 1 | 2017 | 61 | 0.040 |
Why?
| | Pain Management | 1 | 2018 | 135 | 0.040 |
Why?
| | Cost Savings | 1 | 2016 | 39 | 0.040 |
Why?
| | Quality Indicators, Health Care | 1 | 2016 | 44 | 0.040 |
Why?
| | Mental Disorders | 1 | 2018 | 202 | 0.040 |
Why?
| | Patient Care Team | 1 | 2017 | 140 | 0.040 |
Why?
| | Curriculum | 1 | 2016 | 153 | 0.040 |
Why?
| | Early Diagnosis | 1 | 2015 | 76 | 0.040 |
Why?
| | Reproducibility of Results | 1 | 2018 | 857 | 0.040 |
Why?
| | Statistics, Nonparametric | 1 | 2015 | 162 | 0.040 |
Why?
| | Hospital Mortality | 1 | 2016 | 178 | 0.040 |
Why?
| | Kaplan-Meier Estimate | 1 | 2015 | 226 | 0.040 |
Why?
| | Databases, Factual | 1 | 2016 | 357 | 0.040 |
Why?
| | Linear Models | 1 | 2015 | 277 | 0.040 |
Why?
| | Drug Industry | 1 | 2014 | 30 | 0.040 |
Why?
| | Clinical Competence | 1 | 2016 | 268 | 0.030 |
Why?
| | Acquired Immunodeficiency Syndrome | 1 | 2014 | 100 | 0.030 |
Why?
| | Guideline Adherence | 1 | 2014 | 81 | 0.030 |
Why?
| | Survival Rate | 1 | 2015 | 464 | 0.030 |
Why?
| | Inpatients | 1 | 2014 | 132 | 0.030 |
Why?
| | Immunoassay | 1 | 2012 | 42 | 0.030 |
Why?
| | Immunity, Cellular | 1 | 2012 | 70 | 0.030 |
Why?
| | Probability | 1 | 2012 | 107 | 0.030 |
Why?
| | Disease Progression | 1 | 2015 | 843 | 0.030 |
Why?
| | Immunosuppressive Agents | 1 | 2012 | 167 | 0.030 |
Why?
| | Postoperative Complications | 1 | 2012 | 1059 | 0.020 |
Why?
|
|
Reau's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|